Skip Nav Destination
December 9 2022
In this Issue
Table of Contents
Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets
Anxiety Provoking Consultations: Mast Cells and Eosinophils
Are Alternative Donors Now Mainstream in Allogeneic Transplant?
Autoimmune Hemolytic Anemias
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies
Beyond Routine Frontline Therapy of CML
Controversies in Aggressive NHL
Immunotherapy in Multiple Myeloma
Improving Outcomes in ALL
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?
JAK/STAT Inhibition and Beyond in Ph-Negative MPNs
Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies
Long-Term Health Effects of Curative Therapy for Sickle Cell Disease
Managing Thrombocytopenia in Challenging Situations
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia
Maximizing Outcomes in CLL
Multiple Myeloma: Assessing the Patient and the Disease
Novel Approaches in MDS
Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries
Prophylactic Platelet Transfusions
Reproductive and Sexual Health in Sickle Cell Disease
Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?
Thrombosis Prevention and Treatment
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients
To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease
Treatment Approaches for the Multiple Myeloma Patient in 2022
Update in Hemophilia
Updates in Targeted Therapy in Pediatric Leukemia
Von Willebrand Disease
What is New in Classical Bone Marrow Failure Syndromes? (Focus on Management)
What's New in Indolent Lymphoma
Where Are We Headed in Hodgkin Lymphoma?
Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2021;2021:578-586.
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents